NMRA-215 preclinical DIO mouse data: up to 26% with semaglutide

Rhea-AI Filing Summary

Neumora Therapeutics (NMRA) filed an 8‑K announcing positive preclinical data for NMRA‑215. The company reported class‑leading weight loss in diet‑induced obesity mouse studies: up to 19% as a monotherapy with semaglutide‑like induction, and 26% when combined with high doses of semaglutide. The announcement was made on October 27, 2025.

A press release with additional details was furnished as Exhibit 99.1 and incorporated by reference.

Insights

Biotech clinical development analyst

Preclinical mouse data show 19%–26% weight loss signals; early stage.

Neumora disclosed preclinical results for NMRA‑215, an oral NLRP3 inhibitor, in diet‑induced obesity mouse models. Reported effects include up to 19% weight loss as monotherapy with semaglutide‑like induction, and 26% in combination with high doses of semaglutide.

These results are from animal studies, which are an early step and may not translate to humans. The filing characterizes NMRA‑215 as “potentially best‑in‑class” and “highly brain‑penetrant,” framing the mechanism under evaluation rather than establishing clinical efficacy.

The press release was filed as Exhibit 99.1 on October 27, 2025. Subsequent filings may provide clinical plans or human data once available.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Neumora Therapeutics (NMRA) announce about NMRA-215?

Neumora announced positive preclinical results for NMRA‑215 in diet‑induced obesity mouse studies, with weight loss up to 19% as monotherapy and 26% with semaglutide.

What is NMRA-215 according to Neumora's disclosure?

NMRA‑215 is described as a potentially best‑in‑class, highly brain‑penetrant, oral NLRP3 inhibitor.

What were the weight loss results reported for NMRA-215?

Weight loss reached up to 19% as a monotherapy and 26% in combination with high doses of semaglutide in DIO mouse studies.

When did Neumora issue the press release and how is it provided?

The press release was issued on October 27, 2025 and furnished as Exhibit 99.1.

What form did Neumora file for this announcement?

Neumora filed a Form 8‑K under Item 8.01 (Other Events).

Does the filing include human clinical data for NMRA-215?

No. The results disclosed are from diet‑induced obesity mouse studies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 10/27/2025 - 06:34 AM Learn about SEC filing dates

false000188552200018855222025-10-272025-10-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 27, 2025

Neumora Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41802	84-4367680
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
260 Arsenal Place, Suite 1
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 760-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		NMRA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 27, 2025, Neumora Therapeutics, Inc. (the “Company”) issued a press release announcing positive preclinical data for NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor from three diet-induced obesity (DIO) mouse studies. In the studies, NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction and 26% in combination with high doses of semaglutide. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1		Press Release dated October 27, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NEUMORA THERAPEUTICS, INC.
Date:	October 27, 2025	By:	/s/ Michael Milligan
			Michael Milligan Chief Financial Officer